SGLT2i initiators with DKD (N = 6389) | Commercial insurance (N = 2284) | Medicare insurance (N = 4105) | Low CV risk (N = 2797) | Moderate CV risk (N = 3237) | High CV risk (N = 355) | |
---|---|---|---|---|---|---|
CV hospitalization | ||||||
Mean (SD) follow-up time in days | 292.3 (328.5) | 336.3 (368.0) | 267.8 (301.5) | 333.0 (376.0) | 266.4 (284.8) | 207.0 (249.7) |
Rate per 1000 PY (95% CI) | 26.0 (21.6, 30.4) | 16.2 (10.7, 21.6) | 32.9 (26.4, 39.4) | 16.5 (11.5, 21.4) | 31.7 (24.6, 38.9) | 79.5 (40.5, 118.4) |
Kidney hospitalization | ||||||
Mean (SD) follow-up time in days | 294.6 (329.8) | 339.1 (369.4) | 269.9 (302.9) | |||
Rate per 1000 PY (95% CI) | 12.0 (9.0, 15.0) | 5.7 (2.5, 8.9) | 16.5 (11.9, 21.0) | |||
AKI hospitalization | ||||||
Mean (SD) follow-up time in days | 293.5 (330.0) | 338.9 (370.6) | 268.3 (302.2) | |||
Rate per 1000 PY (95% CI) | 22.8 (18.7, 26.9) | 12.3 (7.6, 17.0) | 30.2 (24.0, 36.4) | |||
Discontinuation of SGLT2is | ||||||
Discontinuation, n (%) | 3512 (55.0%) | 1024 (44.8%) | 2488 (60.6%) | |||
Mean (SD) time to discontinuation in days | 300.6 (243.9) | 331.4 (282.5) | 287.9 (225.0) | |||
Median [IQR] time to discontinuation in days | 204 [144, 364] | 221 [143, 420] | 195 [145, 348] | |||
Treatment failure | ||||||
Mean (SD) follow-up time in days | 361.49 (365.96) | 347.14 (371.94) | 369.47 (362.39) | |||
Rate per 1000 PY (95% CI) | 510.46 (492.86, 528.07) | 514.21 (484.06, 544.37) | 508.51 (486.82, 530.19) | |||
Reason for treatment failure | ||||||
SGLT2i discontinuation or switch from SGLT2i to another antidiabetic drug class, n (%) | 3053 (63.6%) | |||||
Addition of another antidiabetic class not used in baseline, n (%) | 1495 (31.1%) | |||||
Initiation of insulin, n (%) | 213 (4.4%) | |||||
Two or more reasons for treatment failure, n (%) | 41 (0.9%) |